camptothecin has been researched along with Liver Diseases in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, QY; Qi, L; Xiao, LX; Yu, ED; Yue, HL; Zhang, XL; Zhou, YQ | 1 |
| Demetter, P; Geurs, F; Knape, S; Ponette, J; Ponette, S; Vandewaeter, S | 1 |
| Gallinger, S; Guindi, M; Moore, M; Moulton, CA; Nanji, S; Pollett, A; Ryan, P | 1 |
| d'Esposito, F; Edwards, RJ; Murray, M; Nebot, N | 1 |
| Budman, D; Byrd, J; Enders Klein, C; Fleming, G; Hohl, R; Hollis, D; Kastrissios, H; Leichman, CG; Marshall, J; Ramirez, J; Ratain, MJ; Rosner, GL; Venook, AP; Villalona, M | 1 |
| Cisar, LA; Compton, LD; Duncan, BA; Elfring, GL; Goel, R; Goldberg, RM; Gruia, G; Hammond, LA; Kuhn, JG; McGovren, JP; Miller, LL; Pirotta, N; Rothenberg, ML; Schaaf, LJ; Sharma, A; Tipping, SJ; Yin, D | 1 |
| Bowling, K; Brubaker, A; Chen, TL; Donehower, RC; Ettinger, D; Forastiere, A; Grochow, LB; Ignacio, V; Lubejko, B; O'Reilly, S; Rowinsky, E; Sartorius, S; Slichenmyer, W; Smith, J | 1 |
| Beijnen, JH; Herben, VM; ten Bokkel Huinink, WW | 1 |
| Baars, JJ; Huibregtse, K; Pinedo, HM; Stieltjes, H; Van der Vijgh, WJ; van Groeningen, CJ | 1 |
| Bishop, J; Clarke, SJ; Dodds, HM; Ong, SY; Rivory, LP | 1 |
1 review(s) available for camptothecin and Liver Diseases
| Article | Year |
|---|---|
Clinical pharmacokinetics of topotecan.
Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Half-Life; Humans; Kidney Diseases; Liver Diseases; Metabolic Clearance Rate; Topoisomerase I Inhibitors; Topotecan | 1996 |
3 trial(s) available for camptothecin and Liver Diseases
| Article | Year |
|---|---|
A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Irinotecan; Kidney Diseases; Liver Diseases; Male; Middle Aged; Neoplasms; Pelvis; Radiotherapy | 2003 |
Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Bilirubin; Camptothecin; Diarrhea; Female; Humans; Infusions, Intravenous; Irinotecan; Liver Diseases; Liver Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Patient Selection | 2006 |
Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Humans; Linear Models; Liver; Liver Diseases; Liver Function Tests; Male; Middle Aged; Topotecan | 1996 |
6 other study(ies) available for camptothecin and Liver Diseases
| Article | Year |
|---|---|
Liver injury in septic mice were suppressed by a camptothecin-bile acid conjugate via inhibiting NF-κB signaling pathway.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Bile Acids and Salts; Blotting, Western; Camptothecin; Cytokines; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Liver Diseases; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Peroxidase; Sepsis; Signal Transduction | 2020 |
Successful and well-tolerated second line therapy with cetuximab, irinotecan, and raltitrexed in progressive liver disease due to metastatic colon cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Humans; Irinotecan; Liver Diseases; Liver Neoplasms; Male; Quinazolines; Thiophenes | 2008 |
Chemotherapy-induced liver injury in metastatic colorectal cancer: semiquantitative histologic analysis of 334 resected liver specimens shows that vascular injury but not steatohepatitis is associated with preoperative chemotherapy.
Topics: Antineoplastic Agents; Camptothecin; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Fatty Liver; Female; Humans; Irinotecan; Liver Circulation; Liver Diseases; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2010 |
Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease.
Topics: Antineoplastic Agents; Biotransformation; Camptothecin; Carboxylesterase; Chronic Disease; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Down-Regulation; Humans; Irinotecan; Liver Diseases; Microsomes, Liver | 2010 |
Altered pharmacokinetics and metabolism of CPT-11 in liver dysfunction: a need for guidelines.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Colonic Neoplasms; Female; Fever; Humans; Infusions, Intravenous; Irinotecan; Liver Diseases; Metabolic Clearance Rate; Middle Aged; Practice Guidelines as Topic; Sleep | 2000 |
Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction.
Topics: Adenocarcinoma; Adenomatous Polyposis Coli Protein; Antineoplastic Agents, Phytogenic; Camptothecin; Cecal Neoplasms; Chemical and Drug Induced Liver Injury; Humans; Irinotecan; Kidney; Kidney Diseases; Liver; Liver Diseases; Liver Neoplasms; Male; Middle Aged; Topoisomerase I Inhibitors | 2001 |